Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

No GRASE For Ibuprofen, No Future In OTC Internal Analgesic Monograph

Executive Summary

Nonprescription products containing ibuprofen can now only be marketed in the US through NDAs. No companies took advantage of a proposed ibuprofen addition to the the internal analgesic, antipyretic and antirheumatic OTC monograph, issued in 2002.

Advertisement

Related Content

OTC Naproxen Labeling: US FDA Advisory Panel Finds Imprecise Direction In PRECISION
OTC NSAIDs Need Additional Label Warnings – FDA Advisory Panel
FDA Expands Acetaminophen, NSAID Labeling Beyond Tentative Final Rule

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS123093

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel